The U.S. Food and Drug Administration has approved a new drug called Abreva for treating cold sores, also known as fever blisters. This drug is designed to be applied externally to the face or lips to help shorten the healing time of these common viral sores. It also aims to reduce symptoms like tingling, pain, burning, and itching that often come with cold sores. This approval makes Abreva available without a prescription, giving people a new option to manage these bothersome and sometimes recurring sores.
Abreva is intended for adults and children who get cold sores, offering a way to potentially speed up recovery and ease discomfort. The approval is based on the drug's label claims, which state it can help with healing and symptom relief. This matters because cold sores can be painful and inconvenient, and having an over-the-counter choice might help people start treatment earlier when symptoms first appear.
One important thing to note is that while Abreva is now approved and available, patients should always read and follow the label instructions carefully. The product is for external use only, and there are warnings about possible allergic reactions or misuse. If you have questions or concerns about using Abreva, or if your symptoms don't improve, it's a good idea to talk to your doctor or a healthcare provider for guidance.